Ads
related to: metastatic prostate cancer survival rate- nmCRPC Treatment Option
31% Risk of Death Decrease
Visit The Patient Site.
- Dosing & Administration
View Recommended Dosage & Learn
About Drug Interactions Here.
- Clinical Information
Read About A Double-Blind, Placebo-
Controlled, Randomized Study.
- mHSPC Treatment Option
32% Risk of Death Decrease
Visit The Patient Site.
- Representatives Available
Stay Informed And Get More Info
From A Team Of Representatives.
- Patient Profiles
Explore Patient Profiles To Assess
A Treatment Option.
- nmCRPC Treatment Option
Search results
Local man is first in the world to receive new therapy for prostate cancer
Local 12 Cincinnati· 7 days agoCancer specialists said as rates of cancer rise in younger people, they want everyone to know the...
Study identifies differences in prostate cancer genomics among a racially and ethnically diverse...
Medical Xpress· 5 days agoA new study led by a UCLA-VA collaborative team looking at the landscape of genomic alterations in...
Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
Zacks· 1 day agoCandel (CADL) surges 431% in the year-to-date period, driven by positive developmental and regulatory updates from the clinical program for CAN-2409 across two different cancer indications.
... in Combination with anti-PD-1 for First Line Recurrent and/or Metastatic Head and Neck Cancer to...
ThePress.net· 5 days agoThe updated interim evaluation (data cut-off: August 31, 2023) of 19 enrolled patients in ASP-1929-181 study suggests that the novel treatment approach of ASP-1929 photoimmunotherapy in combination ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 6 days agoSan Francisco of FG-3246 (FOR46), a potential first-in-class anti-CD46 antibody drug conjugate (ADC) with a MMAE-containing payload, in combination with enzalutamide in patients with
ASCO: J&J's radioligand spurs responses, but 4 deaths mar early results
FierceBiotech· 5 days agoJNJ-6420 is an anti-hK2 antibody-based targeted radioligand therapy that's designed to deliver a...
AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024
WKBN 27 Youngstown· 21 hours agoThe 17 abstracts from Amgen-sponsored and partner-led studies, including one late-breaking oral presentation, demonstrate Amgen's commitment to innovation and meaningfully improving outcomes ...
Docs support drug regulator’s move to withdraw Olaparib for some cancer patients
Investing.com· 6 days agoOlaparib is a chemotherapy drug and is used to treat certain kinds of cancers of the ovaries,...
Rutgers Cancer Institute and RWJBarnabas Health Se | Newswise
Newswise· 6 days agoClinicians and scientists from Rutgers Cancer Institute and RWJBarnabas Health will lead sessions...
ASCO24: An early look at cancer drug study results
BioPharma Dive via Yahoo Finance· 6 days agoClinical trial abstracts posted Thursday ahead of this year’s ASCO meeting give a peek at anticipated datasets from Immunocore, Merus, J&J and Merck &...
Ads
related to: metastatic prostate cancer survival rate